Ticagrelor is a reversible P2Y12 platelet receptor inhibitor used in patients with coronary artery disease. Bentracimab is a monoclonal antibody that targets ticagrelor and immediately reverses its effect, allowing urgent or emergency surgery without excessive hemorrhage.
Clinical trial: REVERSE-IT
Type of monoclonal antibody: Fab fragment
Administration: intravenous infusion
Alternative approaches to ticagrelor reversal:
(1) discontinue and wait for platelet function to normalize (of limited use for urgent surgery)
(2) platelet transfusion with fresh frozen plasma
Adverse effects: thrombosis in 5%
To read more or access our algorithms and calculators, please log in or register.
